Cellectis S.A.

Free public records show Cellectis S.A. in 1 of the markets we cover. It is not a key player in our research.

[1] ClinicalTrials.gov, Studies led by Cellectis S.A. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.

Public data

Free public data on Cellectis S.A.

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

Company facts

Home country
France
Stock listing
NASDAQ: CLLS
Legal name
CELLECTIS
Type
Medicines

Source: Wikidata, Company record Q2943995. Retrieved 13 Nov 2026.

Source: GLEIF, Legal entity record, LEI 5493000KKX5VQ37Q2W83. Retrieved 13 Nov 2026.

Source: SEC EDGAR, Company filings, CIK 1627281. Retrieved 13 Nov 2026.

Trials over time

Studies Cellectis S.A. leads, by the year they started and their phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • No phase (devices, observational)

Source: ClinicalTrials.gov, Studies with Cellectis S.A. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.

Markets where public records show them

Markets we cover where free public records show Cellectis S.A.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.

Topics

The topics of the markets Cellectis S.A. is in.

All topics

Search all reports for Cellectis S.A. All companies